İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

Akademisyen

ELİF AKTAŞ SEPETCİ

Profesör

Sağlık Bilimleri Üniversitesi

Makale 11 YÖKSİS 11 · OpenAlex 0 Q1 makale 6 Scopus · WoS Q1 2
Akademik özet YÖKSİS ve OpenAlex ayrı sayılır.
Makale 11
YÖKSİS11 OpenAlex0
Proje 0
Kitap 0
Bildiri 0

Alan sıralaması

YÖKSİS ?

Dizin çeyrekleri

?
Scopus (SJR) 10
  • Q1 6 %60,0
  • Q2 1 %10,0
  • Q3 3 %30,0
  • Q4 0 %0,0
WoS (JCR) 11
  • Q1 2 %18,2
  • Q2 4 %36,4
  • Q3 2 %18,2
  • Q4 3 %27,3
TR Index 4 makale
Diğer sayımlar

Scopus (SJR)

  • YÖKSİS satırı 10

WoS (JCR)

  • YÖKSİS satırı 11

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

11makale

Yayını olan dergiler

7 dergi

Daralt

Scopus (SJR)
Q16 Q21 Q33 Q40
WoS (JCR)
Q12 Q24 Q32 Q43
TR Index
4makale

Makale listesi

  1. 2025 Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES DOI 10.1007/s10096-024-04990-w YÖKSİS SJR Q1 JCR Q2
  2. 2025 Urinary Salmonella Enteritidis Carriage in a Patient Living with MIKROBIYOLOJI BULTENI DOI 10.5578/mb.202501122 YÖKSİS TR Index SJR Q3 JCR Q4
  3. 2024 The Role of Dynamic Changes in Hematologic and Biochemical Parameters in Predicting Mortality in Covid-19 Patients MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL DOI 10.14744/SEMB.2024.26096 YÖKSİS TR Index JCR Q3
  4. 2024 Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES DOI 10.1007/s10096-024-04896-7 YÖKSİS SJR Q1 JCR Q2
  5. 2024 A New Case of Fournier's Gangrene Caused by Actinotignum schaalii MIKROBIYOLOJI BULTENI DOI 10.5578/mb.20249908 YÖKSİS TR Index SJR Q3 JCR Q4
  6. 2024 In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY DOI 10.1093/jac/dkad396 YÖKSİS SJR Q1 JCR Q2
  7. 2024 Determination of the presence of carbapenemase enzymes in carbapenem-resistant Pseudomonas aeruginosa isolates by susceptibility test based algorithm DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE DOI 10.1016/j.diagmicrobio.2024.116495 YÖKSİS SJR Q2 JCR Q3
  8. 2023 The effects of measures taken during the COVID-19 pandemic on the seasonal dynamics of respiratory viruses in children TURKISH JOURNAL OF PEDIATRICS DOI 10.24953/turkjped.2023.154 YÖKSİS TR Index SJR Q3 JCR Q4
  9. 2023 Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY DOI 10.1093/jac/dkad225 YÖKSİS SJR Q1 JCR Q1
  10. 2023 Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent CLINICAL THERAPEUTICS DOI 10.1016/j.clinthera.2022.12.004 YÖKSİS SJR Q1 JCR Q2
  11. 2023 Phenotypic and genotypic profile of ceftolozane/tazobactam-non-susceptible, carbapenem-resistant Pseudomonas aeruginosa JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY DOI 10.1093/jac/dkac385 YÖKSİS SJR Q1 JCR Q1

← Akademisyenlere dön